Chemical Biology and Drug Design

JUNE 9, 2025

A series of small molecule PD-L1 inhibitors was discovered via optimization of the solvent-interaction region. GJ19 showed the most potent anti-PD-L1 effects with an IC 50 of 32.06 nM. GJ19 (i.p., 15 mg/kg) effectively suppressed tumor growth with a TGI of 56.8% in a B16-F10 melanoma mouse model. ABSTRACT Despite extensive research, the topic of anti-PD-L1 small-molecule inhibitors remains elusive.

Small Molecule

Drug Target Review

JUNE 9, 2025

The landscape of genetic medicine is undergoing a profound transformation, driven by innovative approaches that challenge the traditional, disease-specific paradigms. One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases.

Disease

The Pharma Data

JUNE 9, 2025

WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing endocrine disease treatments, have announced the formal launch of the technology transfer process for the commercial production of lonapegsomatropin.

Therapies

Covalent Modifiers

JUNE 9, 2025

Charlotte M. Zammit, Cory M. Nadel, Ying Lin, Sajjan Koirala, Elnaz Ahani, Patrick Ryan Potts, and Daniel K. Nomura Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c02801 Androgen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or the expression of truncated variants of AR that are constitutively activated.

DNA

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

The Pharma Data

JUNE 9, 2025

Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the prestigious SLEEP 2025 conference, unveiling Phase 4 clinical results that further solidify the therapeutic benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in the management of narcolepsy.

FDA Approval

Drugs.com

JUNE 9, 2025

MONDAY, June 9, 2025 — Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new clinical trial shows. Patients prescribed the combination of finerenone and empagliflozin.

Treatment

Alta Sciences

JUNE 9, 2025

The Golden Era of GLP-1 Drugs: How Will it Impact Medicine and Society? by Dr. Gaetano Morelli MD, Chief Medical Officer and Executive Vice President Medical Affairs pmjackson Mon, 06/09/2025 - 15:32 Synopsis Dr. Morelli explores how rapid advancements in GLP‑1 therapies are transforming treatment paradigms, healthcare systems, and societal health outcomes.

Therapies

The Pharma Data

JUNE 9, 2025

Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for an expanded indication of its RNAi drug AMVUTTRA® (vutrisiran). The new approval authorizes the use of AMVUTTRA for adult patients with cardiomyopathy caused by wild-type or hereditary transthyretin amyloidosis (ATTR-CM).

Treatment

Chemical Biology and Drug Design

JUNE 9, 2025

Erianin suppresses ox-LDL-induced apoptosis and oxidative stress by regulating Nrf2 signaling in HUVECs. ABSTRACT Oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell damage plays an important role in the pathogenesis of atherosclerosis (AS). This study aimed to investigate the ability of Erianin to protect human umbilical vein endothelial cells (HUVECs) against ox-LDL-induced oxidative stress and its underlying mechanisms.

RNA

The Pharma Data

JUNE 9, 2025

Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory syncytial virus (RSV) season, Sanofi has announced that shipments of Beyfortus® (nirsevimab) will begin in early Q3 2025. This early global distribution marks a strategic effort to give healthcare providers ample time to prepare for the upcoming RSV season, which typically begins in November and

Virus

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

New Drug Approvals

JUNE 9, 2025

HEXASODIUM PHYTATE cas 34367-89-0 myo -Inositol, 1,2,3,4,5,6-hexakis(dihydrogen phosphate) sodium salt (1:6) hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate free form RN: 83-86-3 C 6 H 12 Na 6 O 24 P 6 , 791.93 Inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo – (8CI) myo -Inositol, hexakis(dihydrogen phosphate), hexasodium salt (9CI) Hexasodium fytate Hexasodium phytate SNF 472 UNII-ZBX50UG81V CSL-525; Hexasodium phytate; Myo-inositol

Clinical Trials

The Pharma Data

JUNE 9, 2025

FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor). This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season.

FDA Approval

Reprocell

JUNE 9, 2025

Psoriasis is a common chronic skin disease that causes a rash on affected individuals, characterised by itchy, scaly patches. 1 Currently, there is no cure for this disease that affects 2-3% of the worldwide population. 2 Instead, treatment options are focused on management and control rather than healing or eradication. Individuals affected by psoriasis have a few options available to them: topical, systemic and phototherapy, in an attempt to mitigate their symptoms.

Disease

The Pharma Data

JUNE 9, 2025

Merck’s Pimicotinib Accepted for Priority Review in China, Offering Hope for Patients with TGCT Merck , a prominent global science and technology company, announced a significant milestone in its oncology portfolio as the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) officially accepted the company’s application for the marketing authorization of pimicotinib , a novel oral treatment targeting tenosynovial giant cell tumor (TGCT).

Treatment

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

JUNE 9, 2025

"Navigating the Maze of Regulations: How Pharmaceutical Companies Can Safeguard Their Drug Portfolios As the pharmaceutical industry continues to evolve, regulatory environments are becoming increasingly complex. With new laws and guidelines emerging regularly, companies must stay agile to avoid costly delays and maintain market competitiveness.

Pharmaceutical Companies

Pharma Manufacturing

JUNE 9, 2025

The CDMO is building identical large-scale production facilities in the U.S. and Denmark, designed to modularly and seamlessly integrate manufacturing regardless of location.

Production

Science Daily: Pharmacology News

JUNE 9, 2025

Scientists at Weill Cornell Medicine have developed a new algorithm, the Krakencoder, that merges multiple types of brain imaging data to better understand how the brain s wiring underpins behavior, thought, and recovery after injury. This cutting-edge tool can predict brain function from structure with unprecedented accuracy 20 times better than past models and even estimate traits like age, sex, and cognitive ability.

Fierce BioTech

JUNE 9, 2025

Patients, Pipeline & Promise: Software-Enhanced Drugs dwunderlin Mon, 06/09/2025 - 16:54 Thu, 07/24/2025 - 13:00 Resource Type Webinar Anthony Costello David Benshoof Klein Promotion Start Wed, 06/11/2025 - 12:45 Promotion End Thu, 12/11/2025 - 12:45 Software-Enhanced (SE) drugs open new pipelines of opportunity, and allow forward-looking leaders to differentiate their portfolios.

Drugs

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

The Pharma Data

JUNE 9, 2025

WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health Regulations (2005) Emergency Committee on 5 June 2025. The meeting, which ran from 12:00 to 17:00 CEST, concluded with a strong consensus: the current mpox situation continues to constitute a Public Health Emergency of I

Vaccine

Chemical Biology and Drug Design

JUNE 9, 2025

The overall mechanism diagram of ferulic acid delaying renal interstitial fibrosis and inhibiting incomplete EMT of TECs by regulating HIF-1α. ABSTRACT Ferulic acid (FA), a natural phenolic compound, shows potential therapeutic effects on renal interstitial fibrosis, although its antifibrotic mechanism remains unclear. This study investigated the molecular mechanisms of FA by focusing on epithelial-mesenchymal transition (EMT) and related signaling pathways.

Regulations

Fierce BioTech

JUNE 9, 2025

Fueling REMS Program Success via Service and Technology pesurya Mon, 06/09/2025 - 10:26 Tue, 07/22/2025 - 11:00 Resource Type Webinar Carolyn Carr Nikki Walters Brent Weyers Justin Wilson Join Syneos Health experts at the forefront of REMS transformation to learn how leading technology, integrated strategies and operational excellence are redefining what’s possible.

Compliance

Chemical Biology and Drug Design

JUNE 9, 2025

Glutamine reduces WTAP expression and thus upregulates NCOA3 by suppressing WTAP-mediated m6A modification of NCOA3 mRNA, thereby exerting protective activity in ulcerative colitis (UC). ABSTRACT Ulcerative colitis (UC) is a chronic inflammatory condition. Glutamine (Gln) has shown an improved effect on UC. However, its molecular determinants are incompletely understood.

RNA

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Fierce BioTech

JUNE 9, 2025

Widening the Pharma Marketing Funnel with AI-Powered Engagement: Ostro's Approach to Converting Interest into Action Learn how leading pharma brands are boosting digital engagement by applying consumer-tech strategies like AI-driven personalization and intuitive UX. This whitepaper features real-world case studies showing improved HCP and patient conversions. dfarris Mon, 06/09/2025 - 07:51 Learn how leading pharma brands are boosting digital engagement by applying consumer-tech strategies like

Marketing

thought leadership

JUNE 9, 2025

In the highly regulated medical device industry, navigating FDA’s submission process can be daunting, especially for start-ups. However, FDA’s Q-Submission (Q-Sub) program offers a valuable opportunity for early and meaningful interactions with the Agency. This post will delve into the Q-Submission process and its benefits.

FDA

Perficient: Drug Development

JUNE 9, 2025

Creating a More Equitable World In today’s world, designing spaces, products, and digital experiences that work for everyone is no longer optional, it’s essential. Accessibility, inclusive design, and universal design are key approaches that ensure individuals of all abilities can fully participate in society. While these terms are often used interchangeably, each has distinct principles and applications.

Government

Science Daily: Pharmacology News

JUNE 9, 2025

Bumblebee queens don t work nonstop. UC Riverside scientists discovered that queens take strategic reproductive breaks early in colony formation likely to conserve energy and increase the chance of survival. These pauses aren t due to stress but are a built-in response to brood development stages. The study shows queen behavior is far more flexible and dynamic than previously thought, potentially offering new insights into how to protect declining bee populations.

Drugs.com

JUNE 9, 2025

MONDAY, June 9, 2025 -- Artificial intelligence (AI) can boost radiologists’ ability to quickly and accurately assess people’s X-rays, a new study says. Some radiologists became 40% more efficient at reviewing images with the help of a.

Science Daily: Pharmacology News

JUNE 9, 2025

Deep within the brain, the ventral tegmental area does more than signal when we re rewarded it forecasts exactly when we ll be rewarded. This discovery came from an elegant collaboration between neuroscientists and AI researchers, revealing that VTA neurons not only predict the likelihood of future rewards but also their precise timing.

Research

Drugs.com

JUNE 9, 2025

MONDAY, June 9, 2025 — More young women in the United States are being diagnosed with breast cancer and several celebrities have helped raise awareness by sharing their stories. Singer Jessie J, 37, said last week that she has early-stage.

Science Daily: Pharmacology News

JUNE 9, 2025

Planets may begin forming much earlier than scientists once believed during the final stages of a star s birth, not afterward. This bold new model, backed by simulations from researchers at SwRI, could solve a long-standing mystery: why so many exoplanet systems have tight clusters of similarly sized planets orbiting close to their stars. These compact systems seem to emerge naturally if planets start forming amid the swirling chaos of gas and dust still feeding the star.

Research

Drugs.com

JUNE 9, 2025

MONDAY, June 9, 2025 — A salmonella outbreak tied to a major egg recall has sickened nearly 80 people and sent at least 21 to the hospital, health officials have said. The outbreak has been linked to brown organic and brown cage-free eggs.

Hospitals

Codon

JUNE 9, 2025

This article concludes Issue 06. Watch our Behind-the-Scenes interview with the author on YouTube. By Thomas Moynihan In 1832, Ferdinand von Ritgen, a German physician, puzzled over how the first generation of humans birthed themselves. He pictured their embryos sprouting spontaneously “without procreating parents preceding them,” like fungal growths emerging from the ground.

Science